bioAffinity Technologies, Inc. Cash Flow Conversion Efficiency
bioAffinity Technologies, Inc. cash flow conversion efficiency. Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has a cash flow conversion efficiency ratio of -0.352x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.56 Million) by net assets ($7.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of bioAffinity Technologies, Inc. (2019–2025)
Cash flow conversion efficiency of bioAffinity Technologies, Inc. from 2019 to 2025. This chart illustrates how bioAffinity Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest bioAffinity Technologies, Inc. stock price today for real-time trading data and today's change.
bioAffinity Technologies, Inc. Cash Flow Conversion Ratio Explained
bioAffinity Technologies, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
bioAffinity Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their cash flow conversion efficiency. Also see market value of bioAffinity Technologies, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BCM Alliance Bhd
KLSE:0187
|
0.048x |
|
Asuransi Bina Dana Arta Tbk
JK:ABDA
|
0.018x |
|
SMX (Security Matters) Public Limited Company Class A Ordinary Shares
NASDAQ:SMX
|
0.000x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
|
Prairie Provident Resources Inc
TO:PPR
|
0.100x |
|
Bitterroot Resources Ltd
V:BTT
|
-0.003x |
|
Warisan TC Holdings Bhd
KLSE:5016
|
0.095x |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
-1.513x |
Annual Cash Flow Conversion Efficiency for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of bioAffinity Technologies, Inc. from 2019 to 2025. Review bioAffinity Technologies, Inc. financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.28 Million | $-9.33 Million | -1.282x | +54.09% |
| 2024-12-31 | $2.60 Million | $-7.26 Million | -2.792x | -124.51% |
| 2023-12-31 | $4.86 Million | $-6.04 Million | -1.244x | -237.35% |
| 2022-12-31 | $11.04 Million | $-4.07 Million | -0.369x | -384.08% |
| 2021-12-31 | $-15.79 Million | $-2.05 Million | 0.130x | -11.41% |
| 2020-12-31 | $-15.07 Million | $-2.21 Million | 0.146x | -76.26% |
| 2019-12-31 | $-4.04 Million | $-2.49 Million | 0.617x | -- |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more